Skip to main content
Mersana Therapeutics, Inc. logo

Mersana Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRSN ISIN · US59045L1061 LEI · 529900VWD5VDZ7PVOS22 US Manufacturing
Open in API
Filings indexed 700 across all filing types
Latest filing 2024-06-12 Director's Dealing
Country US United States of America
Listing US MRSN

About Mersana Therapeutics, Inc.

https://www.mersana.com/

Mersana Therapeutics, Inc. is a clinical-stage company focused on discovering and developing life-changing antibody-drug conjugates (ADCs) for patients fighting cancer. The company utilizes its proprietary and differentiated ADC platforms, which incorporate both cytotoxic and immunostimulatory payloads, to develop its pipeline. These platforms are designed to customize and optimize ADCs, aiming to overcome the limitations of first-generation technologies by improving efficacy and tolerability. Mersana is advancing a portfolio of ADC candidates to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2024-06-12 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 11, 2024, by Mersana Therapeutics, Inc. It reports the submission of matters to a vote of security holders at the company's 2024 Annual Meeting of Stockholders. The content includes detailed voting results on director elections, advisory vote on executive compensation, and ratification of the independent auditor. This matches the description of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document is not an Annual Report, Earnings Release, or Proxy Statement, but specifically reports the official voting outcomes from the AGM. The length (5264 characters) and detailed vote counts confirm it is the voting results report itself, not just an announcement of a report. Therefore, the correct classification is DVA with high confidence.
2024-06-11 English
SC 13G
Major Shareholding Notification
2024-05-17 English
Regulatory Filings 2024
Regulatory Filings
2024-05-10 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement and accompanying prospectus related to a $100 million at-the-market offering of common stock by Mersana Therapeutics, Inc. It includes detailed information about the terms of the offering, risk factors, use of proceeds, dividend policy, plan of distribution, and legal matters. The document is filed pursuant to Rule 424(b)(5) under the Securities Act of 1933 and is part of a shelf registration statement. This type of document is a capital raising disclosure describing financing activities and terms of a stock offering. It is not an annual or quarterly report, earnings release, management discussion, or any other type of report. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or link to a report, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2024-05-09 English
10-Q
Interim / Quarterly Report Q1 2024
2024-05-09 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.